Literature DB >> 12168113

Granulocyte-colony stimulating factor enhances chimeric antibody Nd2 dependent cytotoxicity against pancreatic cancer mediated by polymorphonuclear neutrophils.

Yutaka Tamamori1, Tetsuji Sawada, Tamahiro Nishihara, Yoshito Yamashita, Masaichi Ohira, Jenny J L Ho, Young-Sik Kim, Kosei Hirakawa-Y S Chung.   

Abstract

Nd2 is a monoclonal antibody against pancreatic cancer. We have previously reported that human/mouse chimeric antibody Nd2 (c-Nd2) can induce antibody-dependent cell-mediated cytotoxicity (ADCC) with peripheral blood mononuclear cells (PBMs) as effectors. In this study, we investigated whether c-Nd2 can induce ADCC with poly-morphonuclear neutrophils (PMNs) as effector cells and the effects of granulocyte-colony stimulating factor (G-CSF) in enhancing this cytotoxicity. Cytotoxicities for pancreatic cancer cell line, SW1990 were dose-dependently increased by c-Nd2 during co-culture with PMNs and these cytotoxicities were significantly suppressed by the addition of neutralizing antibodies against CD16, which is Fcgamma receptor expressed on PMN membranes. PMNs treated with G-CSF significantly enhanced in vitro ADCC activity against SW1990 induced by c-Nd2. The in vivo growth of subcutaneously transplanted SW1990 tumor in nude mouse was significantly inhibited by i.p. administration of c-Nd2 compared to control (non-specific IgG1). In addition, this inhibitory effect was enhanced by the combination of c-Nd2 and G-CSF. Immunohistochemical study with anti-mouse neutrophil elastase antibody demonstrated strong infiltrations of PMNs into and around the transplanted tumor, treated with c-Nd2 and G-CSF. These results suggest that PMNs play an important role in c-Nd2 inducing ADCC and that combination immunotherapy of c-Nd2 with G-CSF may have clinical applications in the treatment of patients with pancreatic cancer by enhancing ADCC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12168113

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  5 in total

1.  Expression of the CXCR6 on polymorphonuclear neutrophils in pancreatic carcinoma and in acute, localized bacterial infections.

Authors:  M M Gaida; F Günther; C Wagner; H Friess; N A Giese; J Schmidt; G M Hänsch; M N Wente
Journal:  Clin Exp Immunol       Date:  2008-09-05       Impact factor: 4.330

2.  Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells.

Authors:  S L Fu; J Pierre; T A Smith-Norowitz; M Hagler; W Bowne; M R Pincus; C M Mueller; M E Zenilman; M H Bluth
Journal:  Clin Exp Immunol       Date:  2008-09       Impact factor: 4.330

3.  Antitumoral effect of maintained neutrophilia induced by rhG-CSF in a murine model of pancreatic cancer.

Authors:  A Brú; R Bosch; M V Céspedes; S Carmona-Güedes; E Pascual; I Brú; J C Souto
Journal:  Sci Rep       Date:  2019-02-27       Impact factor: 4.379

4.  Study of tumor growth indicates the existence of an "immunological threshold" separating states of pro- and antitumoral peritumoral inflammation.

Authors:  Antonio Brú; David Gómez-Castro; Luis Vila; Isabel Brú; Juan Carlos Souto
Journal:  PLoS One       Date:  2018-11-02       Impact factor: 3.240

5.  G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.

Authors:  Paula Martinez Sanz; Dieke J van Rees; Hanke L Matlung; Godelieve A M Tytgat; Katka Franke; Lieke M J van Zogchel; Bart Klein; Panagiota Bouti; Hugo Olsman; Karin Schornagel; Ivana Kok; Ali Sunak; Kira Leeuwenburg; Ilse Timmerman; Miranda P Dierselhuis; Waleed M Kholosy; Jan J Molenaar; Robin van Bruggen; Timo K van den Berg; Taco W Kuijpers
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.